ClinicalTrials.gg
Not yet recruitingNCT07556848Updated Apr 30, 2026

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Phase 3 interventional study of 9MW2821 and Chemotherapy in Locally Advanced or Metastatic Triple-negative Breast Cancer, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 252 studies in Triple Negative Breast Neoplasms with a site in China — 126 open to participants now, 153 under way, 33 of them phase 3. Triple Negative Breast Neoplasms · China.

Planned enrollment
44th of 235
356 · median 90
Started
2026
with 31 others
Phase 3
48 of 252
19 open now
Primary completion
2027-12
later than 108 of 152 live
Registered
243rd of 252
by date

Among the 252 studies in Triple Negative Breast Neoplasms with a site in China, this one is the 44th largest by planned enrollment of the 235 interventional ones that give a count, is one of 32 that started in 2026, is one of 48 in phase 3, reaches primary completion later than 108 of the 152 other live ones, and was the 243rd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

126 of the 252 studies in Triple Negative Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Triple Negative Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload

03

Conditions studied

  • Locally Advanced or Metastatic Triple-negative Breast Cancer

Keywords

  • triple-negative breast cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved form.
  • Male or female subjects aged 18 to 75 years (including 18 and 75 years).
  • 0-1.
  • Histopathological diagnosed triple-negative breast cancer.
  • Patient has previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload.
  • Suitable for one of active comparator chemotherapy assessed by investigator.
  • An sample or a fresh tissue sample should be provided.
  • of ≥ 12 weeks.
  • Subjects must have according to (version 1.1).
  • Adequate organ functions.
  • Sexually active fertile participants, and their partners, must agree to use methods of during the study and at least 6 months after termination of study therapy.

Exclusion criteria

Exclusion Criteria:

  • Preexisting treatment related toxicity Grade ≥ 2 and Grade ≥ 3 immune related adverse reactions.
  • Preexisting peripheral neuropathy Grade ≥ 2.
  • (HbA1c) ≥ 8%.
  • Has ocular conditions or symptoms that may increase the risk of the study.
  • History of ILD or pneumotitis, other severe or uncontrolled disease or central nervous system and/or meningeal metastasis.
  • Previous medication does not meet the requirements.
  • Known sensitivity to any of the ingredients of the product; History of drug abuse or mental illness.
  • Documented history of pulmonary embolism or cardiac or cerebrovascular diseases .
  • Active disease.
  • History of another .
  • Pleural, abdominal, or pericardial effusion with clinical symptoms or that require drainage treatment.
  • Not suitable to receive study treatment for other conditions as per investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (estimated)

Study arms

  • Experimental
    Experimental: 9MW2821

    Participants will receive intravenous (IV) infusion of 9MW2821 as per protocol

    Drug: 9MW2821

  • Active comparator
    Active Comparator: Investigator's Choice of Chemotherapy

    Participants will receive investigator's choice of chemotherapy determined prior to randomization from 1 of the 4 allowed regimens as per protocol: eribulin, or vinorelbine or capecitabine or gemcitabine.

    Drug: Chemotherapy

Interventions

  • Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol

  • DrugChemotherapy

    Participants will receive investigator's choice of chemotherapy determined prior to randomization from 1 of the 4 allowed regimens as per protocol: eribulin, or vinorelbine or capecitabine or gemcitabine.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time from the date of randomization until the date of death from any cause

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate per investigator

    The percentage of subjects who experience a best response of either CR or PR.

    Time frame: Up to approximately 2 years

  2. Duration of Response per investigator

    Time from the date of the first complete response (CR) or partial response (PR) to the earliest date of disease progression or death from any cause.

    Time frame: Up to approximately 2 years

  3. Time to response per investigator

    Time from the date of randomization to the date of CR or PR.

    Time frame: Up to approximately 2 years

  4. Disease Control Rate per investigator

    The percentage of subjects who experience a best response of CR, PR or stable disease (SD).

    Time frame: Up to approximately 2 years

  5. Progression Free Survival per investigator

    Time from the date of first randomization to the earliest date of documented disease progression per radiological evidence or death from any cause.

    Time frame: Up to approximately 2 years

  6. Incidence of adverse events

    Time frame: Up to approximately 2 years

  7. Incidence of Anti-Drug Antibody (ADA)

    Time frame: Up to approximately 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
May 2026
Primary completionEst.
Dec 2027
CompletionEst.
Sep 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556848
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
May 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Jiong Wu
Contact
wujiong1122@vip.sina.com
021-64175590
Jian Zhang
Contact
syner2000@163.com
021-64175590

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulumtatug fuvedotin

Start the discussion